tooluniverse-drug-drug-interaction

Provide the two drug names and the Skill queries DrugBank for documented interactions in both directions, then checks FDA labels, PubMed literature, and FAERS adverse event reports. It outputs a markdown report with a risk score, severity classification, and management recommendations.

The pipeline uses ToolUniverse tools covering RxNorm for drug identification, DrugBank for interaction mechanisms and pharmacology, DailyMed for FDA label warnings, PubMed for clinical literature, and FAERS for post-market adverse event surveillance.

Yes, the Skill supports polypharmacy analysis of three or more medications by computing all pairwise interactions and presenting them in a DDI matrix with an overall polypharmacy risk score and prioritized monitoring schedule.

The score ranges from 0-100, adding points for identified mechanisms, FDA label warnings, literature evidence, and FAERS report volume. Scores of 70+ are classified Major, 40-69 Moderate, and below 40 Minor.

The pipeline depends on DrugBank query results, and name-matching or API failures can return empty interactions. The report explicitly documents failed tool calls and empty results rather than fabricating findings, so verify drug name spelling and retry.

Yes, for major interactions it suggests safer alternatives in the same therapeutic class with different metabolic pathways, such as recommending pravastatin or rosuvastatin instead of simvastatin when combined with strong CYP3A4 inhibitors.